Long-term effects of adding an SGLT-2 inhibitor to insulin therapy in patients with type 1 diabetes. An observational study and systematic review of real-world evidence
SGLT2i addition to insulin therapy in T1D patients resulted in sustained HbA1c reductions and weight loss. Therapy persistence significantly influenced outcomes, underscoring the importance of patient selection and monitoring for adverse effects.
Authors
- Monica Vedovato
- Daniela Bruttomesso (ORCID: https://orcid.org/0000-0002-2426-8955)
- Gian Paolo Fadini (ORCID: https://orcid.org/0000-0002-6510-2097)
- Benedetta Maria Bonora (ORCID: https://orcid.org/0000-0002-6770-2723)
- Federico Boscari (ORCID: https://orcid.org/0000-0002-9670-615X)
- Alberto Maran (ORCID: https://orcid.org/0000-0002-7266-8486)
- Mario Luca Morieri (ORCID: https://orcid.org/0000-0001-6864-0547)
- Carlo Fagarazzi
- Maria Cristina Crepaldi
Institutions
- University of Padua (IT)
- Veneto Institute of Molecular Medicine (IT)
Publication Details
- Journal
- Journal of Endocrinological Investigation
- Published
- 2025-05-10
- DOI
- https://doi.org/10.1007/s40618-025-02602-8
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- Università degli Studi di Padova